The company hopes to accrue around 5,000 patients over the next few years, creating a broad dataset coupling outcomes with comprehensive DNA, RNA, and protein analyses.
Analyst Nicholas Jansen set a price target at $116, pointing to expanding professional lab services, consumer-focused programs, and M&A as growth drivers.
The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
The genetic tests are used to predict chemotherapy toxicity, relapse risk after surgery, and a healthy individual's risk for developing the disease.
The firm said that its CE-marked ePlex Blood Culture Identification fungal pathogen panel is the first of three tests that will become part of its sepsis solution.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.